Figure 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
<p>Kaplan–Meier curves by treatment. The red line represents the ICI–ICI group, and the blue line represents the ICI–TKI group.</p>
Salvato in:
| Autore principale: | |
|---|---|
| Altri autori: | , , , , , , , , , , , , , , , , |
| Pubblicazione: |
2025
|
| Soggetti: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1851482727182761984 |
|---|---|
| author | Bunpei Isoda (22273897) |
| author2 | Masanobu Shiga (22273900) Shuya Kandori (20806494) Shota Takahashi (22273903) Akifumi Omiya (22273906) Tomoki Ishida (22273909) Kotoe Matsuda (22273912) Hiromichi Sakurai (22273915) Bryan J. Mathis (20803922) Ken Tanaka (22273918) Manabu Komine (22273921) Masahiro Iinuma (22273924) Akira Joraku (22273927) Hiromitsu Negoro (17411086) Masakazu Tsutsumi (22273930) Takamitsu Inoue (22273933) Jun Miyazaki (22273936) Hiroyuki Nishiyama (18287202) |
| author2_role | author author author author author author author author author author author author author author author author author |
| author_facet | Bunpei Isoda (22273897) Masanobu Shiga (22273900) Shuya Kandori (20806494) Shota Takahashi (22273903) Akifumi Omiya (22273906) Tomoki Ishida (22273909) Kotoe Matsuda (22273912) Hiromichi Sakurai (22273915) Bryan J. Mathis (20803922) Ken Tanaka (22273918) Manabu Komine (22273921) Masahiro Iinuma (22273924) Akira Joraku (22273927) Hiromitsu Negoro (17411086) Masakazu Tsutsumi (22273930) Takamitsu Inoue (22273933) Jun Miyazaki (22273936) Hiroyuki Nishiyama (18287202) |
| author_role | author |
| dc.creator.none.fl_str_mv | Bunpei Isoda (22273897) Masanobu Shiga (22273900) Shuya Kandori (20806494) Shota Takahashi (22273903) Akifumi Omiya (22273906) Tomoki Ishida (22273909) Kotoe Matsuda (22273912) Hiromichi Sakurai (22273915) Bryan J. Mathis (20803922) Ken Tanaka (22273918) Manabu Komine (22273921) Masahiro Iinuma (22273924) Akira Joraku (22273927) Hiromitsu Negoro (17411086) Masakazu Tsutsumi (22273930) Takamitsu Inoue (22273933) Jun Miyazaki (22273936) Hiroyuki Nishiyama (18287202) |
| dc.date.none.fl_str_mv | 2025-09-19T04:00:15Z |
| dc.identifier.none.fl_str_mv | 10.1158/2767-9764.30162553 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Figure_1_from_Prognostic_Impact_of_Immune-Related_Adverse_Events_on_Combination_Immune_Checkpoint_Tyrosine_Kinase_Inhibition_for_Metastatic_Renal_Cancer/30162553 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Tumor Biology Molecular and Cellular Biology Immuno-oncology Clinical Research and Trials Antibody Immunotherapy Cell Signaling Clinical-stage Research Genitourinary Cancers Renal cancer Immunotherapy Toxicities/irAEs Immune Cells And The Microenvironment Protein Tyrosine Kinases Tumor Microenvironment |
| dc.title.none.fl_str_mv | Figure 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Kaplan–Meier curves by treatment. The red line represents the ICI–ICI group, and the blue line represents the ICI–TKI group.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_374aa1ddf8e7a5c4909a492da3bca79c |
| identifier_str_mv | 10.1158/2767-9764.30162553 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30162553 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Figure 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal CancerBunpei Isoda (22273897)Masanobu Shiga (22273900)Shuya Kandori (20806494)Shota Takahashi (22273903)Akifumi Omiya (22273906)Tomoki Ishida (22273909)Kotoe Matsuda (22273912)Hiromichi Sakurai (22273915)Bryan J. Mathis (20803922)Ken Tanaka (22273918)Manabu Komine (22273921)Masahiro Iinuma (22273924)Akira Joraku (22273927)Hiromitsu Negoro (17411086)Masakazu Tsutsumi (22273930)Takamitsu Inoue (22273933)Jun Miyazaki (22273936)Hiroyuki Nishiyama (18287202)CancerTumor BiologyMolecular and Cellular BiologyImmuno-oncologyClinical Research and TrialsAntibody ImmunotherapyCell SignalingClinical-stage ResearchGenitourinary CancersRenal cancerImmunotherapyToxicities/irAEsImmune Cells And The MicroenvironmentProtein Tyrosine KinasesTumor Microenvironment<p>Kaplan–Meier curves by treatment. The red line represents the ICI–ICI group, and the blue line represents the ICI–TKI group.</p>2025-09-19T04:00:15ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/2767-9764.30162553https://figshare.com/articles/figure/Figure_1_from_Prognostic_Impact_of_Immune-Related_Adverse_Events_on_Combination_Immune_Checkpoint_Tyrosine_Kinase_Inhibition_for_Metastatic_Renal_Cancer/30162553CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/301625532025-09-19T04:00:15Z |
| spellingShingle | Figure 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer Bunpei Isoda (22273897) Cancer Tumor Biology Molecular and Cellular Biology Immuno-oncology Clinical Research and Trials Antibody Immunotherapy Cell Signaling Clinical-stage Research Genitourinary Cancers Renal cancer Immunotherapy Toxicities/irAEs Immune Cells And The Microenvironment Protein Tyrosine Kinases Tumor Microenvironment |
| status_str | publishedVersion |
| title | Figure 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer |
| title_full | Figure 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer |
| title_fullStr | Figure 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer |
| title_full_unstemmed | Figure 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer |
| title_short | Figure 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer |
| title_sort | Figure 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer |
| topic | Cancer Tumor Biology Molecular and Cellular Biology Immuno-oncology Clinical Research and Trials Antibody Immunotherapy Cell Signaling Clinical-stage Research Genitourinary Cancers Renal cancer Immunotherapy Toxicities/irAEs Immune Cells And The Microenvironment Protein Tyrosine Kinases Tumor Microenvironment |